ngs
(10)
Sasan Amini
Sasan Amini is the co-founder and CEO of Clear Labs, a San Carlos genomics company that turns next-generation DNA sequencing into a push-button diagnostic for food safety and infectious disease. An Iranian immigrant who left Tehran at 22, he earned a PhD in genomics at Princeton, worked in advanced research at Illumina, and in 2014 set out to make sequencing simple enough for any lab to run. When COVID-19 hit, Clear Labs pivoted its automated platform into SARS-CoV-2 surveillance and reached more than half of U.S. public health labs.
Complete Genomics
Complete Genomics is a San Jose-based life-science technology company and the Americas arm of MGI. Founded in 2005 as a pioneer of affordable whole-human-genome sequencing, it develops and sells next-generation sequencing instruments, reagents, and analysis software built on its proprietary PCR-free DNBSEQ (DNA nanoball) technology. The company aims to drive down the cost of sequencing - from the landmark $5,000 genome to sub-$100 - and supplies researchers, clinical labs, and biotech companies with a full workflow spanning sample prep, library construction, sequencing, and data analysis.
Apostle Inc
Apostle Inc is a Pleasanton, California biotechnology company that develops nucleic acid isolation and preservation technologies for liquid biopsy. Its flagship magnetic-nanoparticle kit, Apostle MiniMax, extracts circulating cell-free DNA and RNA from blood for applications in early cancer detection, non-invasive prenatal testing, infectious disease research, and even astronaut biospecimen collection in commercial spaceflight. Founded in 2018 out of the Stanford StartX accelerator, the company sells reagents, automation instruments, and CLIA/CAP lab services to researchers and diagnostics developers worldwide.
Paragon Genomics
Paragon Genomics is a Fremont, California biotechnology company that makes it faster and cheaper to read the parts of a genome that actually matter. Its patented CleanPlex amplicon sequencing technology turns tiny or degraded DNA and RNA samples into sequencing-ready libraries in a few hours, powering targeted next-generation sequencing for cancer research, infectious-disease surveillance, inherited-disease testing and agricultural genomics. Founded in 2015 and backed by an $8M Series A, the company sells both ready-to-use and custom NGS panels to more than 300 labs worldwide.
Algorithmic Biologics
Algorithmic Biologics is a Bengaluru- and Delaware-based deep-tech company that treats molecular testing as an information-processing problem. Founded by molecular-computing researcher Dr. Manoj Gopalkrishnan, its patented Tapestry platform uses compressed sensing and combinatorial pooling to run large-scale DNA/RNA/protein tests with far fewer reactions - screening many samples at once and only zooming in where a signal exists. The approach first proved itself as an award-winning, regulator-approved COVID-19 pooling solution and now targets affordable genomics, multiplexed diagnostics, and accelerated assay design.
Jun Ye
Jun Ye is the co-founder, president and CEO of Sentieon, a Mountain View bioinformatics company whose variant-calling software has swept the precisionFDA Truth and Consistency Challenges. A Stanford-trained electrical engineer with more than 50 U.S. patents, he previously co-founded Brion Technologies (acquired by ASML in 2006) and Founton Technologies (acquired into Alibaba in 2012), and taught at Stanford as a consulting professor for fourteen years.
Arima Genomics
Arima Genomics is a Carlsbad, California biotech commercializing Hi-C technology - sequencing methods that reveal the 3D structure of the genome. Its research kits help scientists assemble chromosome-scale genomes and study chromatin architecture, while its clinical brand Aventa Genomics turns the same proximity-ligation chemistry into FFPE-friendly cancer tests for fusions, rearrangements, and other structural variants conventional NGS often misses.
Hiranjith H
Hiranjith H (also Hiranjith GH) is the Chief Business Officer of Algorithmic Biologics, a Bengaluru-founded deeptech startup that embeds algorithms inside test tubes to make molecular testing dramatically cheaper and faster. Based in the San Francisco Bay Area, he leads the company's commercial operations and US expansion. He spent more than a decade scaling MedGenome's research-services business in the US and earlier built commercialization and analytics strategy for life-sciences clients at Novartis, ZS Associates, and Accenture Management Consulting.
Aihua Fu
Aihua Fu is a nanobiotechnologist and the co-founder, President and CEO of NVIGEN Inc., a San Jose nanobiotechnology company building molecularly engineered magnetic and fluorescent nanoparticles for cancer detection and personalized medicine. Trained as a chemist under Nobel-track nanoscience pioneer A. Paul Alivisatos at UC Berkeley and as a postdoc at Stanford, she turned quantum-dot and magnetic-bead research into commercial tools for liquid biopsy, cfDNA extraction, single-cell sequencing and circulating tumor cell capture. Her flagship NVIGEN X and NERNST-Seq platforms aim to read DNA, RNA, protein and cell signals together to predict cancer recurrence early and guide therapy.
Yongwei Zhang
Yongwei Zhang is the CEO of Complete Genomics and MGI Americas, leading one of the most ambitious efforts to make whole-genome sequencing fast, accurate, and affordable at scale. With a PhD in Mechanical Engineering from Johns Hopkins and dual bachelor's degrees from Tsinghua University, Zhang brings a rare blend of optics precision, software fluency, and entrepreneurial grit to the genomics frontier. He architected the DNBSEQ sequencing platform series now used by over 2,600 researchers in 100 countries, and has positioned Complete Genomics as a formidable challenger to Illumina's market dominance - at a fraction of the cost.